礼来:又一款口服减重药启动临床试验

药渡
15 hours ago

▎Armstrong2025年4月25日,礼来又一款口服减重创新药LY4086940在Clinicaltrials.gov网站上注册临床试验。该一期临床试验计划入组165例受试者,预计2026年4月完成。LY4086940通过口服给药。减重为礼来重点布局的治疗领域,有多款创新药处于早期临床阶段。总结礼来已经在GLP-1的迭代竞争中取得全面领先,并借此登顶全球市值第一药企宝座。替尔泊肽为目前已上市的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10